Industry News (Drug Development)

Research Results Announced To Develop Cancer Therapeutic

Published in Cancer Weekly, September 30th, 1996

Demeter BioTechnologies, Ltd., Durham, North Carolina, announced the results of independent in vitro studies which indicated that its proprietary compounds could be effective as a treatment for cancer.

The studies were conducted in the prostate cancer research laboratory of Dr. Cary N. Robertson, M.D., Duke University Medical Center (DUMC) in Durham, North Carolina. The Duke researchers demonstrated in vitro that a single low dose treatment with Demeter's leading anti-cancer Peptidyl MIM (Membrane Interactive Molecule) killed 98 percent of the cell line PC-3, a common prostate cancer model.

The Demeter Peptidyl MIM also was effective against cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-09-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry